Skip to main content

Bragar Eagel & Squire, P.C. Is Investigating Waldencast, Chemours, Trupanion, and Renovaro and Encourages Investors to Contact the Firm

NEW YORK, March 04, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Waldencast Plc (NASDAQ: WALD), The Chemours Company (NYSE: CC), Trupanion Inc. (NASDAQ: TRUP), and Renovaro Biosciences Inc. (NASDAQ: RENB). Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices. Additional information about each case can be found at the link provided.

Waldencast Plc (NASDAQ: WALD)

On April 25, 2023, Waldencast announced that it will be unable to file its 2022 annual report on time and will be postponing its fiscal year 2022 and fourth quarter earnings call due to an ongoing review of the Company’s year-end 2022 financial statements. Specifically, the Company is conducting an analysis regarding certain accounting issues in connection with the sale of certain Obagi products for the Vietnam market. 

On this news, the price of Waldencast shares declined by $0.57 per share, or approximately 6.20%, from $9.20 per share to close at $8.63 on April 25, 2023.

For more information on the Waldencast investigation go to:

The Chemours Company (NYSE: CC)

On February 13, 2024, after the market closed, Chemours disclosed that it was postponing the release of its financial results and conference call related to its fourth quarter and full year 2023. The Company further clarified, stating that it was delaying its results because Chemours is “evaluating its internal control over financial reporting as of December 31, 2023 with respect to maintaining effective controls related to information and communications,” and because the Company’s Audit Committee “needs additional time to complete a related internal review.”

On this news, Chemours’ stock price fell as much as 12% during intraday trading on February 14, 2024, thereby injuring investors.

For more information on the Chemours investigation go to:

Trupanion Inc. (NASDAQ: TRUP)

On February 15, 2024, Trupanion reported preliminary financial results for the fourth quarter and full year ended December 31, 2023, stating that “the Company expects to report two material weaknesses in internal controls.” 

On this news, the price of the Company’s stock dropped.

For more information on the Trupanion investigation go to:

Renovaro Biosciences Inc. (NASDAQ: RENB)

On February 13, 2024, Hindenburg Research ("Hindenburg") published a short report on Renovaro, alleging, among other things, that in the months leading up to the vote on Renovaro's merger with GEDi Cube, "Renovaro enlisted stock promoters, including one previously sanctioned by the SEC, to hype up the GEDi deal and pump shares to retail investors."

Following publication of the Hindenburg repot, Renovaro's stock price fell $1.44 per share, or 42.86%, to close at $1.92 per share on February 13, 2024, damaging investors.

For more information on the Renovaro investigation go to:

About Bragar Eagel & Squire, P.C.:

Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit Attorney advertising. Prior results do not guarantee similar outcomes.

Contact Information:

Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Marion Passmore, Esq.
(212) 355-4648

Primary Logo

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.